Boehringer Ingelheim’s volasertib for acute myeloid leukemia (AML) has been granted Orphan Drug Designation by the FDA and European Commission. Volasertib is being evaluated in a Phase III trial for the treatment of patients aged 65 or older, with previously untreated AML, who are ineligible for intensive remission induction therapy.   Volasertib is an investigational compound that inhibits Plk1 enzymes, which regulates cell division and can result in prolonged cell cycle arrest, ultimately lead...